Lack of clinically significant pharmacokinetic interaction between the 3-DAA combination of AL-335, odalasvir and simeprevir for the treatment of chronic HCV infection and an oral contraceptive containing ethinylestradiol and drospirenone

Conference Reports for NATAP

18th International Workshop on
Clinical Pharmacology of Antiviral Therapy
June 14-17, 2017
Chicago, Ill.C


Lack of clinically significant pharmacokinetic interaction between the 3-DAA combination of AL-335, odalasvir and simeprevir for the treatment of chronic HCV infection and an oral contraceptive containing ethinylestradiol and drospirenone

	Reported by Jules Levin 18th International Workshop on Clinical Pharmacology of Antiviral Therapy, 14-16 June 2017, Chicago, IL,USA Ouwerkerk-Mahadevan S1, Gamil M1, van Hemelryck S1, Hillewaert V1, van Nimwegen M2, Kakuda T3, Biermer M1 1Janssen Research & Development, Janssen Pharmaceutica NV, Beerse, Belgium; 2Janssen Biologics BV, Leiden, Netherlands; 3Alios BioPharma, Inc., part of the Janssen Pharmaceutical Companies, South San Francisco, USA Short Duration Treatment with AL-335 and Odalasvir, with or without Simeprevir, in Treatment Naïve Patients with Hepatitis C Infection with or without Cirrhosis - (04/24/17) AL-335, A ONCE-DAILY PANGENOTYPIC NUCLEOTIDE HCV POLYMERASE INHIBITOR, DEMONSTRATES POTENT ANTIVIRAL ACTIVITY OVER 7 DAYS IN TREATMENT-NAïVE GENOTYPE 1-4 PATIENTS - (04/18/16) PAN-GENOTYPIC EVALUATION OF AL-335, A CLINICAL STAGE URIDINE ANALOG INHIBITOR OF HEPATITIS C VIRUS POLYMERASE - (04/18/16) Preclinical Characterization of AL-335, a Potent Uridine Based Nucleoside Polymerase Inhibitor for the Treatment of Chronic Hepatitis C - (05/05/15)